THE EFFECT OF METFORMIN ON BODY WEIGHT IN POLYCYSTIC OVARY SYNDROME PATIENTS
DOI:
https://doi.org/10.29121/granthaalayah.v2.i3.2014.3057Keywords:
Polycystic Ovary Syndrome, Metformin, Diabetic, Insulin Resistance, Body Mass IndexAbstract [English]
Polycystic Ovary Syndrome (PCO) is an endocrine disease that is characterized by a set of symptoms including irregular menstruation, subfertility, skin changes, hirsutism and weight gain.
The pathogenesis of PCO is mostly related to increase androgens and insulin resistance. Treatment is mostly symptomatic hence metformin is being used due to its effect in decreasing gluconeogenesis and by increasing peripheral utilization of glucose, in addition to its lowering effects on androgen. Thus, Metformin role in PCO treatment ranges between managing insulin resistance, promoting ovulation and treating hirsutism to some extent. Some studies showed that Metformin is effective in lowering body weight in PCO patients, yet it is not being indicated officially for this purpose.
Background: Metformin is expected to have an effect of weight reduction in PCO patients This is the scope of this research which intends to explore this action.
Method: The Study design is cross sectional study using online questionnaire. Open and closed ended questions were included.
Results: Based on the results the majority shows decrease in the weight, while only one reported increase in their weight and only one had the same weight during and after treatment with metformin.
Conclusions: Metformin generally showed positive effect regarding reducing the body weight of the females diagnosed with polycystic ovarian syndrome when used alone.
Downloads
References
. Mathur, R., et al., Use of metformin in polycystic ovary syndrome. American journal of obstetrics and gynecology, 2008. 199(6): p. 596-609. DOI: https://doi.org/10.1016/j.ajog.2008.09.010
. Franks, S., Polycystic ovary syndrome. New England Journal of Medicine, 1995. 333(13): p. 853-861. DOI: https://doi.org/10.1056/NEJM199509283331307
. Atiomo, W. and A. Sinha, The role of metformin in the treatment of infertile women with polycystic ovary syndrome. The Obstetrician & Gynaecologist, 2004. 6(3): p. 145-151. DOI: https://doi.org/10.1576/toag.6.3.145.26996
. Carmina, E. and R.A. Lobo, Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. Journal of Clinical Endocrinology & Metabolism, 1999. 84(6): p. 1897-1899. DOI: https://doi.org/10.1210/jcem.84.6.5803
. Lorig, K.R., et al., Internet-based chronic disease self-management: a randomized trial. Medical care, 2006. 44(11): p. 964-971. DOI: https://doi.org/10.1097/01.mlr.0000233678.80203.c1
. Baker, P.N. and L. Kenny, Obstetrics by ten teachers. 2011: CRC Press. DOI: https://doi.org/10.1201/b13484
. Polycytic ovary syndrome. 2014 30-4-2014]; Available from: http://www.uptodate.com/contents/polycystic-ovary-syndrome-pcos-beyond-the-basics.
. BNF, British national formulary. Vol. 65. 2013: Pharmaceutical Press.
. Ehrmann, D.A., Polycystic ovary syndrome. New England Journal of Medicine, 2005. 352(12): p. 1223-1236. DOI: https://doi.org/10.1056/NEJMra041536
. Harborne, L.R., et al., Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. Journal of Clinical Endocrinology & Metabolism, 2005. 90(8): p. 4593-4598. DOI: https://doi.org/10.1210/jc.2004-2283
. De Groot, P., et al., PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Human reproduction update, 2011. 17(4): p. 495-500. DOI: https://doi.org/10.1093/humupd/dmr001
. Glintborg, D., et al., Body composition is improved during 12 months treatment with metformin alone or combined with oral contraceptives compared to treatment with oral contraceptives in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 2014. DOI: https://doi.org/10.1210/jc.2014-1135
. Dunaif, A., Insulin action in the polycystic ovary syndrome. Endocrinology and metabolism clinics of North America, 1999. 28(2): p. 341-359. DOI: https://doi.org/10.1016/S0889-8529(05)70073-6
. Diamanti-Kandarakis, E., Insulin sensitizers targeting metabolic and reproductive consequences in polycystic ovary syndrome, in Polycystic Ovary Syndrome. 2008, Springer. p. 197-215. DOI: https://doi.org/10.1007/978-1-59745-108-6_13
Downloads
Published
How to Cite
Issue
Section
License
With the licence CC-BY, authors retain the copyright, allowing anyone to download, reuse, re-print, modify, distribute, and/or copy their contribution. The work must be properly attributed to its author.
It is not necessary to ask for further permission from the author or journal board.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
